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and glycemic control in type 1 diabetic patients with and without residual b-cell function.
RESEARCH DESIGN AND METHODS—Ten type 1 diabetic patients with residual
b-cell function (C-peptide positive) and 19 without (C-peptide negative) were studied. All
C-peptide–positive patients were treated with liraglutide plus insulin, whereas C-peptide–neg-
ative patients were randomly assigned to liraglutide plus insulin or insulin monotherapy. Con-
tinuousglucosemonitoringwithidenticalfoodintakeandphysicalactivitywasperformedbefore
(week 0) and during (week 4) treatment. Differences in insulin dose; HbA1c; time spent with
blood glucose ,3.9, .10, and 3.9–9.9 mmol/L; and body weight were evaluated.
RESULTS—Insulin dose decreased from 0.50 6 0.06 to 0.31 6 0.08 units/kg per day (P ,
0.001)inC-peptide–positivepatientsandfrom0.7260.08to0.5960.06units/kgperday(P,
0.01) in C-peptide–negative patients treated with liraglutide but did not change with insulin
monotherapy. HbA1c decreased in both liraglutide-treated groups. The percent reduction in
daily insulin dose was positively correlated with b-cell function at baseline, and two patients
discontinued insulin treatment. In C-peptide–positive patients, time spent with blood glucose
,3 . 9m m o l / Ld e c r e a s e df r o m3 . 0t o1 . 0h( P = 0.03). A total of 18 of 19 patients treated with
liraglutide lost weight during treatment (mean [range] 22.3 6 0.3 kg [20.5 to 25.1]; P ,
0.001). Transient gastrointestinal adverse effects occurred in almost all patients treated with
liraglutide.
CONCLUSIONS—Treatmentwithliraglutideintype1diabeticpatientsreducesinsulindose
with improved or unaltered glycemic control.
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G
lucagon-like peptide-1 (GLP-1) is
secretedfromthegutaftermeals(1)
and enhances glucose-induced in-
sulin secretion, inhibits glucagon secre-
tion, and delays the gastric-emptying
rate (1). GLP-1 receptor agonists improve
glycemic control, induce weight loss in
overweight subjects with type 2 diabetes
(2–4), improve pancreatic b-cell function
(5), and have displayed b-cell–protective
and b-cell–proliferative effects in some
animal studies (6). The glucose-lowering
effects resulting from the inhibition of glu-
cagon secretion and the gastric-emptying
rate could be of clinical importance in
type 1 diabetes (7–14). However, GLP-1
also reduces appetite and spontaneous
food intake (15,16). Therefore, potential
beneﬁcial effects in terms of reduction
of insulin dose, reduced risk of hypoglyce-
mia, and improved glycemic control
should be balanced against the occurrence
of adverse effects (mainly nausea) and
weight loss. We investigated whether
4 weeks of treatment with liraglutide, a
once-daily human GLP-1 receptor analog,
would reduce insulin dose while preserv-
ing or improving glycemic control and de-
creasing the risk of hypoglycemia in type 1
diabetic patients with and without residual
b-cell function.
RESEARCH DESIGN AND
METHODS—Ten type 1 diabetic pa-
tients with (C-peptide positive) and 20
without (C-peptide negative) residual
b-cell function were recruited. All C-
peptide–positive patients were treated
with liraglutide plus insulin for 4 weeks,
whereas C-peptide–negative patients
were randomly assigned to either 4
weeks of liraglutide plus insulin or insu-
lin alone (control subjects). We expected
treatment effect to be smallest in the
C-peptide–negative group, and because
eligible C-peptide–positive patients are
difﬁcult to recruit, we only included
C-peptide–negative patients as control
subjects. It was calculated that with nine
patientsineachgroupandanSDof15%,a
change in insulin dose of 30% would be
detected at a 5% signiﬁcance level with
80% probability. Patients were recruited
through outpatient clinics; they agreed to
participate and provided oral and written
information,andthestudywasperformed
according to the principles of the Helsinki
2 Declaration. The following were the in-
clusion criteria: age 18–50 years, BMI
18–27 kg/m
2, Caucasian descent, diag-
nosed between the ages of 5 and 40 years,
remission period was assumed to be
ended, no known late diabetes complica-
tions (except microalbuminuria), no use
ofmedicationknowntoaffectglucoseme-
tabolism, or symptomsof autonomic neu-
ropathy. Participants were excluded if
screening revealed not previously recog-
nized late diabetes complications, auto-
nomic neuropathy (see below), anemia,
or HbA1c .8.5%. The study (clinical trial
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Clinical Care/Education/Nutrition/Psychosocial Research
ORIGINAL ARTICLEreg. no. NCT00993720) was surveyed by
the good clinical practice unit, Bispebjerg
Hospital, Denmark, and approved by the
Danish Medicines Agency and the Danish
DataprotectionBoard.Beforeenteringthe
study, glycemic control was evaluated for
4 days with self-monitored blood glucose
measurements six to seven times daily,
and, if needed, insulin dose was corrected
to ensure the best possible glycemic con-
trol before entering the study.
Screening procedures
Screening was performed in the morning
after an overnight fast. The night before,
usual long-acting insulin was injected,
but no insulin was taken in the morning.
Blood samples were collected for analysis
of HbA1c, liver enzymes, creatinine, total
cholesterol, LDL, HDL, VLDL, triglycer-
ides, islet cell antibodies, and GAD-65.
Measurementsofweight,height,andrest-
ing blood pressure were carried out. Au-
tonomic neuropathy (orthostatic systolic
blood pressure drop .20 mmHg after 0,
1, or 2 min of standing and/or a beat-to-
beat variation during deep breathing of
,10 bpm [R-R variation at electrocardio-
gram] [17]) was assessed. To determine
residual b-cell function, blood glucose
wasraisedto15mmol/Lwithintravenous
bolus of glucose, and C-peptide was mea-
suredbeforeand6minafteranintravenous
bolusof1mgglucagoninjected2minafter
blood glucose was raised. Patients were
classiﬁed as C-peptide negative if stimu-
lated plasma C-peptide was below the
detection limit (,0.03 nmol/L) and as
C-peptide positive if $0.06 nmol/L.
Insulin dose, mean blood glucose,
24-h glucose proﬁles, and blood
samples
In week 0 and week 4, subjects carried a
blinded continuous glucose-monitoring
system (iPro2; Medtronic, København,
Denmark) for 3 days. Patients were al-
lowed to live their daily life and followed
their own individual routine for food in-
take and physical activity but had to re-
produce meals as well as physical activity
between the two study periods. There-
fore, for each patient, day 1 in week
0 and day 1 in week 4 were similar with
respect to meals and physical activity and
so on for days 2 and 3. However, days 1,
2, and 3 were not required to be identical
or comparable within or between pa-
tients. Patients kept logbook recordings
of insulin injections and performed no
less than seven daily blood glucose
measurements. IPro2 uses a retrospective
algorithm to convert sensor signal to
glucose values based on self-monitored
capillary blood glucose readings (18).
Therefore, all patients received a glucose
meter (Contour; Bayer Diabetes Care,
Lyngby, Denmark) to ensure uniform
measurements for conversion of sensor
signals. Patients were requested to main-
tain the same level of glycemic control
during the two time periods and to adjust
insulin dose accordingly. Changes in
mean insulin dose, mean blood glucose,
24-h glucose proﬁles, fasting, as well as
peak postprandial blood glucose during
2 h after breakfast were evaluated from
the logbook and continuous glucose-
monitoring data. Hypoglycemic time,
normoglycemic time, and hyperglycemic
timewerecalculatedfromthe24-hglucose
proﬁles and deﬁned as time spent with a
blood glucose ,3.9, between 3.9 and 10,
and .10 mmol/L, respectively. The pri-
maryendpointwaschangeinmeaninsulin
dose, and secondary end points were
changes in 24-h glucose proﬁles, glycemic
control, mean blood glucose, and body
weightbetweenweeks0and4.Bloodsam-
ples were collected during weeks 0 and 4.
Randomization procedures
C-peptide–negative patients were ran-
domly assigned to liraglutide plus insu-
lin or insulin alone after completion of
the ﬁrst continuous glucose-monitoring
period. Patients opened an envelope con-
taining the randomization code generated
according to www.randomization.com
and sealed by a person not otherwise in-
volved in the study.
Study medication
The dose for liraglutide was 0.6 mg daily
for the ﬁrst week and 1.2 mg daily for the
rest of the study. If severe gastrointestinal
adverse effects (vomiting) occurred, dose
escalationwaspostponedorreduceduntil
recovery. The dose of fast-acting insulin
was decreased by 50% and long-acting
insulin by 0–20% at the start of liraglutide
(0% if morning blood glucose was .7
mmol/L and up to 20% if values were
lower). Insulin dose was then titrated up
or down to meet a target blood glucose of
5–7 mmol/L according to at least 7-point
blood glucose proﬁles (before and after
meals and at bedtime) for the next 3
days. All patients received a telephone
follow-up once daily for the ﬁrst 3 days
and once in the second treatment week
to ensure proper glycemic control and to
record adverse effects. Patients also were
allowedtoadjusttheirinsulindoseduring
the study, and they all received a chart
with target blood glucose and suggested
insulin adjustments.
Meal test and bicycle exercise test:
C-peptide–negative patients
randomly assigned to liraglutide
After an overnight fast, patients con-
sumed a mixed meal consisting of 1,303
KJ (29.2% fat, 14.3% protein, and 52.2%
carbohydrates) with 200 mL water plus
300mLcoffeeortea(optional).Beforethe
meal, patients injected their usual dose
of fast-acting insulin during week 0, and
during week 4 they injected the new dose
(if changed) plus liraglutide. After 2 h in
a recumbent position, patients performed
a 45-min exercise test on a stationary
bicycleergometer. Selectedworkloadwas
50% of the maximal watt performance
during a max watt test. Frequent blood
samples for plasma glucose and glucagon
were collected. End points were time to
hypoglycemia (plasma glucose #2.8
mmol/L) andrate offallinplasma glucose
(mmol/L per min).
Statistical analyses and calculations
Data are means 6 SE. Comparisons of
differences between normally distributed
data were carried out with a two-tailed
Studentttest(pairedwithinandunpaired
between groups) and nonnormally dis-
tributed data with a Mann-Whitney U test
between groups and Wilcoxon test for
paired differences within groups. Spear-
man correlation analysis was used for cal-
culations of correlation coefﬁcients. Area
under the plasma concentration curves
were calculated using the trapezoidal rule.
Differences resulting in P values ,0.05
were considered statistically signiﬁcant.
RESULTS—One C-peptide–negative
patient who was randomly assigned to
liraglutide was excluded as a result of
protocol violation. The C-peptide–positive
(n = 10) and the C-peptide–negative pa-
tients treated with liraglutide (n =9 )o r
insulin (n = 10) were characterized as fol-
lows: age 27.0 6 1.5, 35.7 6 2.2, and
32.9 6 1.7 years; male-to-female ratio
9 to 1, 9 to 0, and 9 to 1; BMI 24.6 6 0.9,
24.6 6 0.7, and 23.1 6 0.6 kg/m
2;d i -
abetes duration 3.7 6 0.8, 17.3 6 2.5,
and 23.1 6 1.6 years; GAD-65 positivity
9/1,4/5,and8/2;isletcellantibodiespos-
itivity1/9,1/8,and4/6;HbA1c6.66 0.3,
7.5 6 0.2, and 7.1 6 0.3%; and stimu-
lated C-peptide 0.45 6 0.01 (range
0.08–0.94), ,0.03, and ,0.03 nmol/L,
respectively.
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Effect of liraglutide in type 1 diabetesInsulin dose
In liraglutide-treated patients, total daily
insulin dose decreased signiﬁcantly but
did not change in patients treated with
insulin alone (Table 1). The signiﬁcance
of the absolute change persisted after
comparison with patients treated with
insulin alone (20.194 6 0.03 and
20.13 6 0.04 vs. +0.017 6 0.02 units/
kg per day; P , 0.001 and P = 0.003 in
C-peptide–positive and –negative pa-
tients,respectively).Inliraglutide-treated
C-peptide–positive and –negative pa-
tients, fast-acting insulin decreased from
0.26 6 0.04 to 0.14 6 0.03 units/kg per
day (P , 0.001) and from0.39 6 0.05 to
0.28 6 0.03 units/kg per day (P =0 . 0 1 )
and long-acting from 0.24 6 0.03 to
0.17 6 0.04 units/kg per day (P =0 . 0 1 )
and from 0.33 6 0.05 to 0.31 6 0.05
units/kg per day (P = 0.02) with a mean
relative reduction of 247.8 6 10.7%
(range 213 to 2100) and 215.8 6
5.5% (+8.3 to 237.3). Two patients
(with stimulated C-peptide of 0.6 and
0.8 nmol/L, respectively) completely dis-
continued insulin treatment without loss
of glycemic control. In C-peptide–positive
patients, the relative reduction in insulin
dose correlated positively with stimulated
C-peptide at week 0 (r = 0.69, P = 0.03).
No C-peptide–negative patients discon-
tinued insulin therapy. The change in in-
sulin dose did not correlate with weight
loss (r =0 . 0 3 ,P =0 . 8 ) .
Glycemic control
In both groups of liraglutide-treated pa-
tients,HbA1cdecreased inweek 4 (Table 1),
but changes were not statistically differ-
ent from the change in patients treated
with insulin alone (20.26 6 0.1 and
20.47 6 0.15 vs. 20.18 6 0.1%; P =
0.7 and P = 0.12) in C-peptide–positive
and –negative patients, respectively,
whereas mean blood glucose (during
continuous blood glucose monitoring)
showednochangeineithergroup(Table
1). In C-peptide–positive patients, time
spent in hypoglycemia decreased sig-
niﬁcantly from 3.0 6 0.9 to 1.0 6 0.4 h
(P = 0.03) (Fig. 1), but compared with
patients treated with insulin alone,
changesinhypoglycemiaorhyperglycemia
were not signiﬁcant (22.03 6 0.70 vs.
20.49 6 0.72 h, P = 0.17 and +0.38 6
0.7vs.20.2860.5h,P=0.6).C-peptide–
negative patients treated with liraglutide
experienced no signiﬁcant changes in
time spent with hypo- or hyperglycemia,
but normoglycemic time changed from
15.5 to 16.9 h (P = 0.4) as a result of a
tendency (P = 0.17) for decreased hypo-
glycemia (Fig. 1). In patients treated with
insulin alone, there were no changes in
HbA1c (P = 0.1), mean blood glucose
(P = 1.0), or 24-h glucose proﬁles (Fig. 1).
In C-peptide–positive and in C-peptide–
negative patients treated with liraglu-
tide and insulin, fasting blood glucose
(mmol/L) changed from 5.46 6 0.46 to
5.95 6 0.44 (P =0 . 3 0 ) ,f r o m5 . 4 46 0.64
to6.5060.35(P=0.09),andfrom5.676
0.61 to 6.54 6 1.09 (P =0 . 3 5 ) ;p e a kp o s t -
prandial blood glucose (mmol/L) from
8.09 6 0.48 to 8.98 6 0.54 (P = 0.08),
from 11.12 6 0.44 to 10.43 6 0.86
(P = 0.43), and from 11.32 6 1.12 to
10.43(P=0.54);anddifferenceschanged
from 2.51 6 0.62 to 2.76 6 0.62 (P =
0.43), from 4.64 6 1.03 to 2.77 6 0.45
(P = 0.07), and from 4.73 6 0.79 to
3.58 6 0.90 (P = 0.31). Thus, the effect
of liraglutide was not predominantly ex-
erted via lowering of postprandial glu-
cose excursions.
b-Cell function
In eight C-peptide–positive patients, we
repeated the glucagon test in week 4 (two
patients refused to repeat the test because
of nausea during the ﬁrst test). Blood glu-
cose was 15.8 6 0.5 and 15.7 6 0.4
mmol/L before injection of glucagon in
week 0 and 4, respectively, but stimu-
lated C-peptide did not change (0.52 6
0.11 vs. 0.46 6 0.08 nmol/L; P =0 . 4 ) .
TheC-peptideresponseafterbloodglucose
was raised to 15 mmol/L but, immediately
before injection of glucagon, changed
from 0.25 6 0.05 to 0.33 6 0.06 nmol/L
(P =0 . 1 8 )
Meal test and bicycle exercise test
Fasting plasma glucose values were iden-
tical between study days (7.97 6 0.8
mmol/L [week 0] and 8.01 6 0.7 mmol/L
[week 4]; P =0 . 9 )( F i g .2 A). Patients were
injected with 7.44 and 5.44 units of fast-
acting insulin in weeks 0 and 4, respec-
tively (P = 0.04). Despite this, there were
no differences of incremental or total
area under the curve (AUC)0–120 min of
plasma glucose between study days.
Three patients stopped cycling prema-
turely because of hypoglycemia in both
week 0 and 4 (one patient both times),
and one additional patient had to stop
prematurely after 25 min of cycling be-
cause of vomiting in week 4 (with plasma
glucose 5.4 mmol/L). Thus, only six and
ﬁve patients completed the cycling test in
week 0 and 4, respectively. If hypoglycemia
occurred (and exercise therefore termi-
nated), the last observed plasma glucose
value was carried forward. During cycling,
total and incremental AUC120–190 min
of plasma glucose changed from 487 6
109 to 391 6 55 mmol/L per min (P =
0.9) and from 2150 6 46 to 2173 6 30
mmol/L per min (P = 0.6)in week 0 and 4,
respectively. The exercise-induced de-
cline in plasma glucose (120–165 min)
did not differ (0.102 6 0.018 mmol/L
per min [week 0] vs. 0.092 6 0.0107
Table 1—Changes in insulin dose, mean BG, HbA1c, and stimulated C-peptide in type 1 diabetic patients with (C-peptide positive)
and without (C-peptide negative) residual b-cell function before (week 0) and during (week 4) 4 weeks of treatment with
liraglutide or insulin alone
Treatment
C-peptide positive C-peptide negative C-peptide negative
Liraglutide + insulin Liraglutide + insulin Insulin only
Week 0 Week 4 Week 0 Week 4 Week 0 Week 4
Insulin dose (units/kg per day) 0.50 6 0.06 0.31 6 0.08* 0.72 6 0.08 0.59 6 0.06† 0.62 6 0.04 0.64 6 0.05 (NS)
Mean blood glucose (mmol/L) 6.0 6 0.2 6.3 6 0.3 (NS) 7.5 6 0.4 7.7 6 0.4 (NS) 7.5 6 0.4 7.5 6 0.6 (NS)
HbA1c (%) 6.6 6 0.3 6.4 6 0.2† 7.5 6 0.2 7.0 6 0.1† 7.1 6 0.3 6.9 6 0.2 (NS)
C-peptide (pmol/L)‡ 520 6 106 457 6 79 (NS) ——— —
Dataaremeans6SE.Meanbloodglucoselevelsarederivedfromcontinuousglucosemonitoringasmeanvaluesduring3dayswithidenticalfoodintakeandphysical
activity in week 0 and week 4. NS, nonsigniﬁcant vs. week 0 in the same group. *P , 0.001 and †P , 0.05 vs. week 0 in the same group. ‡n =8 .
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Kielgast and Associatesmmol/L per min [week 4]; P =0 . 6 ) .F a s t -
ing glucagon were identical (7.9 6 0.3
vs. 7.1 6 0 . 8p m o l / L )i nw e e k0a n d4
(P =0 . 4 ) ,b u tt o t a lA U C 0–120 min of glu-
cagon signiﬁcantly decreased from
1,106 6 92 pmol/L per min (week 0)
to 845 6 70 pmol/L per min (week 4)
(P=0.002); however, during exercise-
induced decrease in plasma glucose,
glucagon increased in both study days
(Fig. 2B).
Adverse effects and patient
satisfaction
Almostallpatientstreatedwithliraglutide
complained of initial gastrointestinal ad-
verse effects, among which nausea was
most frequent (18 of 19), but vomiting (2
of 19), abdominal distension (5 of 19),
diarrhea (3 of 19), and foetor ex ore (3 of
19) also occurred. In most cases, gastro-
intestinal adverse effects were only pres-
ent for the ﬁrst 2–3d a y so ft r e a t m e n t ,
except in two patients who only tolerated
0.9 mg because of vomiting and diarrhea
at 1.2 mg. Most patients reported loss of
appetite(unrelatedtonausea)throughout
the study. Seven C-peptide–positive and
two C-peptide–negative patients wanted
to continue liraglutide treatment after the
end of the trial. All C-peptide–positive
and eight C-peptide–negative patients
treated with liraglutide lost weight,
amounting to 22.8 6 0.3 kg and
21.8 6 0.6 kg, respectively. The mean
difference was 22.3 6 0.3 and +0.2 6
0.3 kg in liraglutide and in patients
treated with insulin alone, respectively
(P,0.001).Weightlossdidnotcorrelate
with BMI, but no patients became under-
weight (BMI ,20.0 kg/m
2). With insulin
alone there was no change in weight and
no occurrence of gastrointestinal adverse
effects. There were no changesin liver en-
zymes, kidney function, white blood cell
count, lipids, or blood pressure between
week 0 and week 4 in any group.
CONCLUSIONS—This is the ﬁrst re-
port that directly compares the effect of 4
weeks of liraglutide treatment on insulin
dose and glycemic control in type 1 di-
abetic patients with and without residual
b-cell function. The major ﬁnding was a
reduction in insulin dose, which was sig-
niﬁcant in both groups of patients treated
with liraglutide and also compared with
patients treated with insulin alone. The
reduction was accompanied by un-
changed time spent with blood glucose
.10 mmol/L, whereas HbA1c and time
spent with blood glucose ,3.9 mmol/L
tended to be reduced. Fast-acting insulin
accounted for 63 and 85% of the reduc-
tion in insulin dose inC-peptide–positive
and –negative patients, respectively. This
is in accordance with a previous study
(13) in which 6 months’ treatment with
exenatide in C-peptide–positive patients
with longstanding disease decreased total
insulin by 13% but prandial insulin by
30% and also with a short-term study in
C-peptide–negative adolescents in which
exenatide reduced glucose excursions
despite a 20% reduction in insulin dose
(14). The current study also was inspired
byprevious short-term trialsusing intrave-
nous or subcutaneous infusion of native
GLP-1 in type 1 diabetic patients. In pa-
tientswithloworundetectableC-peptide
levels,pharmacologicalconcentrationsof
GLP-1 were shown to reduce fasting
plasma glucose from 13.4 to 10 mmol/L,
glucagon concentration by 50% (8), and
isoglycemic meal–relatedinsulinrequirement
Figure 1—Blood glucose evaluated from 24 h continuous glucose monitoring as mean blood
glucoseduring3dayswithself-reportedidenticalmealsandphysicalactivitybefore(week0)and
during (week 4) treatment with liraglutide. A: A total of 10 type 1 diabetic patients with residual
b-cell function treated with liraglutide and insulin. B: A total of nine type 1 diabetic patients
without residual b-cell function treated with liraglutide and insulin. C: A total of 10 type 1 di-
abetic patients without residual b-cell function treated with insulin alone. *P , 0.05 between
week 0 and week 4 within the same group.
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Effect of liraglutide in type 1 diabetesby 50% (12). Furthermore, subcutaneous
exenatide or human GLP-1 administered
together with the usual dose of insulin
safely improved glucose control inpatients
without (7,11)aswellaswith(10)residual
b-cell function.
In most cases, the antidiabetes ef-
fects were accompanied by a reduction
of glucagon levels and/or by delayed
gastric emptying. Therefore, inhibition
o fg a s t r i ce m p t y i n ga sw e l la sr e d u c e d
glucagon levels seem to explain the
glucose-regulating effects of GLP-1
during a meal, whereas the importance
of residual b-cell function is less well de-
ﬁned. In the current study using liraglu-
tide,inhibitionofgastricemptyingmaybe
lessimportantbecauseofthedevelopment
of tachyphylaxis during continuous expo-
sure (19).
In our study, the reduction in insulin
dose was larger in C-peptide–positive pa-
tients, and two patients completely dis-
continued insulin treatment without loss
of glycemic control. Despite reduced in-
sulin doses, neither fasting nor peak post-
prandial blood glucose measurements
differed signiﬁcantly between weeks
0 and 4 in any group. This is in accor-
dance with our goal of preserving the
same (good) glycemic control during the
two periods. However, there were weak
trends of higher mean postprandial levels
in C-peptide–positive patients and of
higher fasting levels in C-peptide–negative
patientstreatedwithliraglutide.Thiscould
theoretically result from worsening of gly-
cemic control but also, and more likely,
fromreducedoccurrenceofhypoglycemia.
It may be argued that part of the reduction
in insulin dose was attributed to the initial
reduction in the liraglutide-treated pa-
tients. However, this is highly unlikely be-
causeallpatientswereoptimizedininsulin
dosebeforeenteringthestudy andbecause
insulin dose afterward was titrated up or
down to meet the same target blood glu-
cose according to careful examination of
at least 7-point blood glucose measure-
ments for 3 consecutive daysimmediately
after start of treatment and in week 2. In
C-peptide–positive patients, HbA1c de-
creased from 6.6 to 6.4% and from 7.5
to 7.0% in C-peptide–negative patients
treatedwithliraglutide,inbothinstances,
with a tendency for decreased hypogly-
cemia,butthisdidnotchangeinpatients
treatedwithinsulinalone.Thereduction
in HbA1c may partly result from a carry-
over effect from the optimization in insulin
therapy before entry. However, all patients
were dose adjusted if necessary, and ran-
dom assignment took place after the initial
correction, and HbA1c did not change in
patients treated with insulin alone.
Alimitationofthecurrentstudyisthe
lack of blinding because of unavailable
placebo pen devices. However, proper
blinding would have been difﬁcult be-
cause of the necessary reduction in insulin
dose (for safety reasons) in liraglutide-
treated patients and because of the gastro-
intestinal adverse effects. The reduction in
insulin dose could theoretically also re-
sult from reduction in appetite, leading
to an unintended (and unreported) de-
crease in carbohydrate intake in week 4
or from improved insulin sensitivity. How-
ever, change in insulin dose was not corre-
l a t e dw i t hw e i g h tl o s s .
The lack of increments in glucose-
stimulated as well as glucagon-stimulated
C-peptide secretion during liraglutide
treatment is puzzling but is in agreement
withRotheretal.(13),inwhich6months’
treatment with exenatide did not change
the b-cell response to arginine.
The weight loss in the liraglutide-
treated patients occurred (in 18 of 19
treated patients) despite encouragements
to maintain body weight, but weight loss
did not correlate with BMI. Nausea and
vomiting occurred only in the ﬁrst 2–3
treatment days and resolved spontane-
ously or subsequent to dose reduction,
but patients also reported loss of appetite
unrelated to nausea. Because almost all
liraglutide-treated patients experienced
Figure 2—Timecourse of plasmaglucose (A) andglucagon (B) during amixedmealfollowedby
45 min cycling (120–165 min) in nine type 1 diabetic patients before (week 0, blue circles) and
during(week 4, red circles) treatment with liraglutide. Arrow:meal served. Iftwo-wayrepeated-
measures ANOVA resulted in signiﬁcant difference (time 3 trial), Student paired t tests were
performed at each time point. *P , 0.05.
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Kielgast and Associatestransient gastrointestinal adverse effects,
start dose should perhaps have been re-
duced.
We could not demonstrate a change
in risk of hypoglycemia during cycling.
However, in week 4, postprandial gluca-
gon was signiﬁcantly reduced but in-
creased appropriately during exercise,
when glucose levels fell; therefore, it
appears that liraglutide, like GLP-1 (20),
does not inhibit the glucagon response to
decreasing glucose levels.
Four weeks’ treatment with liraglu-
tide reduces insulin dose in type 1 dia-
betic patients along with improved or
unaltered glycemic control. Treatment ef-
fect is larger in patients with residual
b-cell function, and some patients may
discontinue insulin treatment. Almost all
patients treated with liraglutide lost
weight.
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